Wikipedia -WSS

Wikipedia

author：knowledge 2025-09-30 17:27:52 - browse：748

Adobe

The Food and Drug Administration has cleared Otsuka Pharmaceutical’s digital treatment for major depressive disorder, offering a new option for millions of people who struggle with the stubborn mental health condition.

Called Rejoyn, the smartphone-based treatment for major depressive disorder symptoms was developed with digital health company Click Therapeutics, and it is intended for use by prescription alongside antidepressants. The six-week program delivers a novel “cognitive-emotional training” technique, in which people are asked to identify and recall faces showing different emotions. Researchers hypothesize that the technique targets the brain’s dorsolateral prefrontal cortex and the amygdala and may “enhance cognitive control over emotional information processing.” Patients also receive cognitive behavioral therapy.

Rejoyn has been in development since 2018, and Otsuka is the first drug company to receive FDA clearance for a digital treatment for a mental health condition. But that landmark comes amid many questions about whether such digital therapeutics deliver their advertised results — and whether they can gain traction with clinicians, insurers, and patients. Prescription digital therapeutics have yet to see a blockbuster success, and several companies have gone out of business trying to create one.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Stopping antidepressants leads to symptoms for 1 in 6 patients

leisure time

WSS

Stopping antidepressants leads to symptoms for 1 in 6 patients

H5N1 bird flu virus started spreading in cows in Texas in December

ASCO Daily Recap: CAR

Eli Lilly’s Zepbound improved liver scarring in mid

Anthony Fauci pushes back on GOP claims during Covid hearing

An outdated Medicare rule harms dementia patients with anxiety

focus

Wikipedia

focus

In age of alternative facts, a scholarly course on calling out crap

UnitedHealth financials solid despite Change Healthcare cyberattack

Drug repurposing or repositioning? The language matters

ASCO Takeaways: Winners, snoozers, and the art of cancer care

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Orangutan used medicinal plant to treat wound, first time ever seen

The cancer drug shortage isn’t new — and neither are the solutions

UnitedHealth CEO's Medicaid comments send insurer stocks diving

How to save PrEP access — and even expand it

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

knowledge

Illumina board agrees to spin off Grail, as divestment plans proceed

Cancer researcher Catriona Jamieson is sending tumors into space

Medical bills so high, Medicare adding extra digits to claim forms

CMS got Medicare Advantage quality rating wrong, judge rules

How CO2 helps viruses stay alive longer in the air

Congress needs to close a vaccine

leisure time

hotspot

knowledge

focus